Skip to main content
Premium Trial:

Request an Annual Quote

SAIC-Frederick Taps Silicon Kinetics Technology for Protein Interaction Research

NEW YORK (GenomeWeb News) – SAIC-Frederick will use Silicon Kinetics’ technology platform to study protein interactions in cancer and AIDS and to determine how drugs affect those interactions, Silicon Kinetics said today.
 
Under the agreement, National Cancer Institute contractor SAIC-Frederick will use Silicon Kinetics’ three-dimensional, label-free SKi Pro Biomolecular Interaction Analysis Platform in its Protein Chemistry Laboratory to study extracellular binding domains of specific proteins linked to these diseases.
 
The partnership was struck through the NCI’s Advanced Technology Partnerships Initiative, which is focused on translating research discoveries into treatments for AIDS and cancer patients.
 
The SKi Pro platform combines nanoporous silicon and optical interferometry to study proteins on 3D biosensor surfaces, Silicon Kinetics said.
 
The company said that the SKi Pro platform and its SKi Sensor biochips are used to detect protein-protein, protein-drug, or protein-DNA interactions in real time, quantifying binding kinetics, and for other studies of disease pathways and in therapeutic development.
 
Financial terms of the agreement were not released.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.